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BaCKgRoUND aND aIMS: The lack of immunocompe-
tent small animal models for hepatitis C virus (HCV) has 
greatly hindered the development of effective vaccines. Using 
rodent hepacivirus (RHV), a homolog of HCV that shares 
many characteristics of HCV infection, we report the devel-
opment and application of an RHV outbred rat model for 
HCV vaccine development.
appRoaCH aND ReSUltS: Simian adenovirus 
(ChAdOx1) encoding a genetic immune enhancer (truncated 
shark class II invariant chain) fused to the nonstructural (NS) 
proteins NS3-NS5B from RHV (ChAd-NS) was used to vac-
cinate Sprague-Dawley rats, resulting in high levels of cluster 
of differentiation 8–positive (CD8+) T-cell responses. Following 
RHV challenge (using 10 or 100 times the minimum infec-
tious dose), 42% of vaccinated rats cleared infection within 
6-8 weeks, while all mock vaccinated controls became infected 
with high-level viremia postchallenge. A single, 7-fold higher 
dose of ChAd-NS increased efficacy to 67%. Boosting with 
ChAd-NS or with a plasmid encoding the same NS3-NS5B 
antigens increased efficacy to 100% and 83%, respectively. A 
ChAdOx1 vector encoding structural antigens (ChAd-S) was 
also constructed. ChAd-S alone showed no efficacy. Strikingly, 
when combined with ChAd-NS, ChAD-S produced 83% effi-
cacy. Protection was associated with a strong CD8+ interferon 
gamma–positive recall response against NS4. Next-generation 
sequencing of a putative RHV escape mutant in a vaccinated 
rat identified mutations in both identified immunodominant 
CD8+ T-cell epitopes.
CoNClUSIoNS: A simian adenovirus vector vaccine strat-
egy is effective at inducing complete protective immunity in 
the rat RHV model. The RHV Sprague-Dawley rat chal-
lenge model enables comparative testing of vaccine platforms 
and antigens and identification of correlates of protection and 
thereby provides a small animal experimental framework to 
guide the development of an effective vaccine for HCV in 
humans. (Hepatology 2020;71:794-807).
Hepatitis C virus (HCV) infects 1.75 million people per year, with over 399,000 deaths annually.(1) Despite direct-acting antivirals 
to treat HCV, an effective vaccine is still urgently 
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required, not least because of low diagnosis rates in 
many populations(2) and difficulty treating at-risk 
groups.(3) HCV vaccine studies have been hampered 
by the lack of a small animal model.(4) A rodent 
homolog of HCV, related but assigned as separate 
species in the genus Hepacivirus, family Flaviviridae, 
was recently discovered in New York brown (sewer) 
rats.(5,6) Infection of the brown rat (Rattus norvegicus) 
by the rodent hepacivirus (RHV) is the basis for our 
vaccine model.
RHV in rats has a profile very similar to that of 
HCV, making it an appropriate surrogate model for 
vaccine study.(6) Like HCV, it is hepatotropic, gener-
ating persistent viremia detectable for over 1 year,(6,7) 
and recapitulates many aspects of liver pathology, 
including microvesicular and macrovesicular steatosis, 
lymphoid aggregation, and evidence of biliary epithe-
lial damage.(6) RHV is predicted to encode similar 
proteins to HCV and possesses similar genetic struc-
tures in the untranslated regions flanking the coding 
region.(6)
The first clinical trial of HCV vaccine efficacy 
in humans, using adenoviral and modified vac-
cinia virus ankara (MVA) vaccines to elicit T-cell 
responses against HCV nonstructural antigens, has 
concluded in the United States (clinical trial no. 
NCT01436357). A press release suggests the vac-
cine failed to protect against natural HCV infec-
tion in this high-risk group (people who inject 
drugs).(8-10) It is now vital to understand why this 
strategy failed. Reaching this stage has been made 
difficult by the lack of appropriate animal models 
for preclinical vaccine development, in particular for 
testing protective efficacy prior to trial.(4) An ideal 
small animal model would be an immunocompetent 
mouse or rat susceptible to HCV infection, man-
ifesting persistence and liver pathology. Despite 
great efforts in this area, including development of 
transgenic(11) and humanized(4,12,13) mice, no system 
until now has met all these requirements.
Most information on potential HCV vaccine 
 efficacy has come from chimpanzees, with antibody- 
generating(14,15) and T cell–based(16-19) vaccines show-
ing evidence of protective efficacy. Both mechanisms 
of protection are implicated in spontaneous resolution 
of HCV infection in humans(20-22) and chimpan-
zees.(23,24) All strategies face difficulties dealing with 
the enormous genetic diversity of HCV,(3,25) leading 
to a recent focus targeting conserved HCV genomic 
regions.(26) Further questions on vaccine efficacy can-
not be answered in chimpanzees because of a recent 
moratorium on using chimpanzees in biomedical 
research.(27)
For these reasons, development of a small animal 
model is critically important for HCV vaccine devel-
opment. Such a model has been developed in inbred 
Lewis rats using a human adenoviral vector.(7) Here, 
we develop the model in outbred Sprague-Dawley 
(SD) rats, more closely mirroring human diversity, 
with a more clinically relevant chimpanzee adenovi-
rus. We believe the SD rat RHV model will be highly 
beneficial to the HCV vaccine field in refining opti-
mal antigens, delivery platforms, adjuvants, and prime/
boost regimes, all of which can help inform difficult 
and expensive clinical trials before they begin. The 
model is also suited to dissecting mechanisms of pro-
tection, questions difficult, if not impossible, to answer 
in humans.
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In the present study we examined the protective 
efficacy of a simian adenovirus encoding nonstruc-
tural or structural antigens against RHV challenge in 
outbred rats. The utility of the model is demonstrated 
by finding that a T-cell response focused on nonstruc-
tural antigens is partially protective and can be greatly 
enhanced by boosting either with a second dose of 
adenovirus or a plasmid encoding the same antigens 
or with a higher single dose of adenovirus. The effi-
cacy of vaccination using structural antigens alone and 
in combination with nonstructural antigens is also 
explored for RHV. Importantly, our results show that 
vaccination resulting in aviremic protection is possible 
against an HCV-like hepacivirus.
Materials and Methods
etHICS StateMeNt
All animals and procedures were used in accordance 
with the terms of the UK Home Office Animals Act 
Project Licence and approved by the University of 
Oxford Animal Care and Ethical Review Committee 
(PPL 30/3293 and P874AC0F0).
Rat StRaINS
Outbred male SD rats (Charles River, UK), 225-
250 g at the start of the experiment, were kept under 
conventional conditions in individually ventilated 
cages and fed a normal chow diet.
INFeCtIoN oF RatS
Serum from one rat infected with RHV-rn1 
(accession no. KX905133) was used as the inoc-
ulum for all challenge experiments. Serum was 
diluted to 105 viral particles (vp) of RHV in 100 µL 
phosphate-buffered saline (PBS) per dose, unless 
otherwise stated, administered into the tail vein. 
Titration of RHV to determine the 100% minimum 
infectious dose (MID) was performed by 1:10 dilu-
tion series from 106 vp.
VaCCINeS
An RHV immunogen, coding for the nonstruc-
tural 3 (NS3) to NS5 region of RHV-rn1 with GDD 
to AAG NS5B mutation, was synthesized using 
Mus musculus codons (GeneArt; ThermoFisher). 
The construct included a Kozak sequence, trun-
cated shark invariant chain, and V5 epitope tag. SIi-
RHV-NS3-NS5mut-V5 was cloned into a pENTR4 
vector downstream of the human cytomegalovirus 
immediate early promoter and tetracycline operator. 
The coding cassette was moved to the ChAdOx1 
destination vector using Thermo Fisher LR gateway 
cloning, and all steps were checked by sequencing. 
ChAdOx1 plasmids incorporating SIi-RHV-NS3-
NS5mut-V5 linearized with PmeI were transfected 
into T-REx-293 cells (Thermo Fisher) for gen-
eration of viral-vector vaccines. ChAdOx1-SIi-
RHV-NS3-NS5mut-V5 (ChAd-NS) vaccines were 
manufactured by the Viral Vector Core Facility 
( Jenner Institute, University of Oxford). An iden-
tical process was followed for production of a 
ChAdOx1 vector encoding RHV antigen core, E1, 
E2, p7, and NS2 (ChAd-S).
VaCCINatIoN
Rats were vaccinated by intramuscular injection 
into the right hind thigh muscle using 50 µL viral 
vector or DNA plasmid in PBS. Typically, 108 infec-
tious units (i.u.) of adenovirus vaccine or 100 µg 
DNA plasmid were administered per dose, unless 
otherwise stated. A second vaccine when adminis-
tered was done 11 weeks following the first vacci-
nation (Table 1).
taBle 1. Vaccination and Challenge Regimes
Group Initial Vaccination (Dose) Boost Vaccination (Dose) Challenge Dose (vp of RHV)
ChAd-NS (1E6 challenge) ChAd-NS (1 × 108 i.u.) — 1 × 106 vp
ChAd-NS (1E5 challenge) ChAd-NS (1 × 108 i.u.) — 1 × 105 vp
ChAd-NS (single high dose) ChAd-NS (6.8 × 108 i.u.) — 1 × 105 vp
ChAd-NS/ChAd-NS ChAd-NS (1 × 108 i.u.) ChAd-NS (1 × 108 i.u.) 1 × 105 vp
ChAd-NS/DNA ChAd-NS (1 × 108 i.u.) DNA (100 µg) 1 × 105 vp
Mock vaccination ChAd-GFP (1 × 108 i.u.) — 105 or 106 vp
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ISolatIoN oF lyMpHoCyteS
Peripheral blood mononuclear cells (PBMCs) 
were isolated from tail vein blood using a Vacutainer 
(Fisher Scientific). Blood was centrifuged (5,000 
rpm), the pellet was resuspended in 1 mL ammo-
nium–chloride–potassium (ACK) lysing buffer (Life 
Technologies; 3-5 min at room temperature [RT]), 
diluted in 10 mL PBS, and centrifuged (5 min, 1,800 
rpm). The pellet was resuspended in R10: Roswell 
Park Memorial Institute (Sigma), 10% fetal bovine 
serum (Sigma), 1% L-glutamine (Sigma), and 1% 
penicillin/streptomycin (Sigma).
Splenocytes were isolated from rat spleens by dis-
ruption through a 70-µm cell strainer and centrifuged 
(1,200 rpm, 5 min, 4°C), and the pellet was resuspended 
in 3 mL ACK lysing buffer (2 minutes, RT). PBS 
was added to 25 mL, centrifugation was performed as 
before, and the pellet was resuspended in R10.
Liver-infiltrating lymphocytes were obtained 
by perfusion of the liver with PBS and disruption 
through a 100-µm then a 50-µm cell strainer. Cells 
were centrifuged (5 minutes, 1,500 rpm), and the pel-
let was resuspended in 40% Percoll (GE). An under-
lay of 70% Percoll was applied, and samples were 
centrifuged (2,000 rpm, 25 minutes without brake). 
Fat and debris were removed and interphase was col-
lected, diluted in PBS, and centrifuged (1,500 rpm, 
5 minutes). The pellet was resuspended in 3 mL ACK 
and treated as for splenocytes.
FloW CytoMetRy
Cells were stimulated overnight with pools of 
15–amino acid peptides overlapping by 11, spanning 
the whole RHV polypeptide sequence (1 µg/mL). 
Dimethyl sulfoxide (DMSO) was applied to nega-
tive controls and phorbol 12-myristate 13-acetate/
ionomycin to positive controls. Mouse antirat clus-
ter of differentiation 28 (CD28; BD Pharmingen, 
1:62.5) was added to each well. One million to 3 
million PBMCs per well were incubated with pep-
tide pools or controls (2 hours, 37°C) then Golgi 
Plug (BD Pharmingen; 1:1,000, 16-18 hours, 
37°C). After incubation with mouse antirat CD32 
(BD Pharmingen; 1:100, RT, 15 minutes), a sur-
face-staining cocktail was applied (30 minutes) 
(Supporting Table S3), followed by fixation and per-
meabilization (Cytofix/Cytoperm; BD Biosciences), 
cell washing (Perm/Wash buffer; BD Biosciences), 
and intracellular staining (30 minutes) (Supporting 
Table S1). Cells were acquired on an LSR II cytom-
eter, and the results were analyzed using FlowJo 
software (version 10).
eNZyMe-lINKeD 
IMMUNoSoRBeNt Spot
MAIP enzyme-linked immunosorbent spot 
(ELISpot) plates (Millipore) were coated overnight 
with 10 µg/mL antirat interferon gamma (IFNγ; 
Mabtech). Frozen splenocytes were thawed and 
stimulated in R10 with pools of peptides, individ-
ual peptides (4  μg/mL), or DMSO-negative con-
trol. Following incubation (37°C, 18-20 hours), 
plates were washed in PBS and treated with antirat 
IFNγ development reagents per the manufacturer’s 
instructions (Mabtech). Results were expressed as 
background-subtracted spot-forming units per mil-
lion splenocytes.
SeRUM RNa eXtRaCtIoN
Serum was collected in a Microvette (Sarstedt) 
from the tail vein of rats. RNA from serum samples 
was extracted using the QIAamp Viral RNA Mini 
Kit per the manufacturer’s instructions.
QUaNtItatIVe pCR
Quantitative PCR to determine genome equiva-
lents of RHV per milliliter of serum was performed 
as described,(6) using a Quantifast SYBR Greeen 
RT-PCR kit (Qiagen), with copy numbers determined 
against a standard curve of full-length RHV RNA.
NeXt-geNeRatIoN SeQUeNCINg
RNA was extracted from blood samples using a 
viral RNA mini kit (Qiagen). RNA was subjected 
to complementary DNA and second-strand DNA 
synthesis using SuperScript III reverse transcriptase 
(Invitrogen) and Sequenase, version 2.0 (Thermo 
Fisher). Libraries were prepared from DNA using 
Nextera XT kit (Illumina) and sequenced on the 
MiSeq platform with the reagent kit (500 cycles). 
After adapter removal and quality trimming, reads 
were aligned against the reference sequence (Genbank 
no. KX905133) using Bowtie2, and variant calling was 
performed using GATK with HaplotypeCaller.
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StatIStICS
Statistical tests for association of immune responses 
with challenge outcome were performed using the 
Kruskal-Wallis test with Dunn’s test correcting for 
multiple comparisons. Comparison of final viremic 
status for each vaccination regime with mock- 
vaccinated rats was performed using Fisher’s exact test.
Results
RHV MID
To determine the MID of RHV, the inoculum was 
titrated by 10-fold dilution and administered to SD 
rats (n = 3/group) (Fig. 1). Mock infection produced 
no detectable viremia by quantitative PCR. A dose of 
1 × 103 RNA genome copies (vp) of RHV resulted in 
two thirds of rats infected. Doses between 1 × 104 and 
1  ×  106 vp resulted in 100% infection. Unless indi-
cated otherwise, 10 × MID at 1 × 105 vp of RHV was 
used for challenge studies.
IMMUNe ReSpoNSeS to RHV 
INFeCtIoN IN UNVaCCINateD 
RatS
The cellular immune response was quantified in 
six unvaccinated SD rats infected with 106 vp. A time 
course of blood CD4+IFNγ+ (Supporting Fig. S1) and 
CD8+IFNγ+ (Fig. 2) responses 4 weeks postinfec-
tion revealed minimal response to any peptide pools 
spanning the RHV polyprotein. The only exception 
was a high but transient CD8+IFNγ+ response in two 
rats 7 days postinfection, with no discernible effect 
on viremia. Splenocyte (Supporting Fig. S2A,B) and 
liver-infiltrating lymphocyte (Supporting Fig. S2C,D) 
responses were minimal.
IMMUNogeNICIty oF 
aDeNoVIRUS VeCtoR VaCCINe 
eNCoDINg NoNStRUCtURal 
pRoteINS oF RHV
A simian adenovirus (ChAdOx1) vector vaccine 
was constructed encoding nonstructural proteins of 
RHV linked to a truncated shark invariant chain 
known to enhance T-cell responses (ChAd-NS) 
(Fig. 3A).(28) A time course of CD4+IFNγ+ 
(Supporting Fig. S3A) and CD8+IFNγ+ (Fig. 3B) 
PBMC responses revealed little or no CD4+IFNγ+ 
response, but a CD8+IFNγ+ response focused on 
NS4 peaked 4 weeks after vaccination with a mean 
of 0.3% NS-specific CD8+IFNγ+ T cells (Fig. 3C). 
These results were similar in splenocytes (Fig. 3D; 
Supporting Fig. S3B) and liver-infiltrating lympho-
cytes (Fig. 3E; Supporting Fig. S3C).
epItope MappINg oF 
IMMUNoDoMINaNt peptIDeS 
IN INFeCteD aND VaCCINateD 
RatS
Three RHV-infected rats showed mini-
mal response to any 15-mer peptide spanning 
the RHV polyprotein except one from the core 
FIg. 1. Determination of MID of RHV. Male SD rats (n = 3/group) were administered varying doses of RHV (103, 104, 105, or 106 vp) 
by intravenous injection into the tail vein. Viremia was determined from blood sampling 7, 14, and 28 days postinfection by quantitative 
PCR and expressed as RHV genome equivalents per millilitre of plasma.
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region (Supporting Fig. S4A). In a vaccinated rat 
one peptide from the NS3 region and two from 
NS4 (Supporting Table S1) elicited strong CD8+ 
responses (Supporting Fig. S4B,C).
pRoteCtIVe eFFICaCy oF 
Chad-NS VaCCINe agaINSt RHV 
CHalleNge
To test the efficacy of ChAd-NS vaccination, SD rats 
(n = 6) were vaccinated with 1 × 108 i.u. and challenged 
4 weeks later with 1 × 105 vp (Supporting Fig. S5A). 
All mock-vaccinated rats rapidly developed high vire-
mia, sustained until end of trial (EOT; approximately 
150 days postinfection) (Fig. 4A). All rats vaccinated 
with ChAd-NS became infected, but two of six 
showed no detectable viremia in blood by 6-7 weeks 
postinfection, a status unchanged by EOT (Fig. 4B). 
Increasing the challenge dose to 1  ×  106 vp showed 
little effect on efficacy: three of six rats cleared infec-
tion 6-7 weeks later and remained clear until EOT 
(Fig. 4C). This equates to a combined efficacy of 42% 
using 1 × 108 i.u. ChAd-NS (Supporting Fig. S5C).
To determine whether additional vaccination 
strategies could improve efficacy, two groups of six 
SD rats were primed with 1  ×  108 i.u. ChAd-NS 
and boosted 11 weeks later with a second dose of 
1  ×  108 i.u. ChAd-NS (Fig. 4D) or 100 µg DNA 
plasmid encoding the same antigens (Fig. 4E). A 
third group of rats (n = 6) was administered a single 
7-fold higher ChAd-NS vaccine dose of 6.8 × 108 
i.u. (Fig. 4F). All groups were challenged 4 weeks 
after final vaccination with 1 × 105 vp (Supporting 
Fig. S5A; Table 1). These groups displayed substan-
tially greater protection than rats receiving a single 
dose of 1 × 108 i.u. ChAd-NS, at both day 28 and 
EOT (Supporting Fig. S5B,C). For the ChAd-NS 
boost, DNA boost, and single high-dose groups, 
efficacy was 100% (P  =  0.001), 83% (P  =  0.008), 
and 67% (P  =  0.03), respectively (Supporting 
Fig. S5C).
Six rats out of the 18 forming these latter three 
groups showed no evidence of viremia (aviremia) at 
any time point, consistent with “sterilizing” immu-
nity. Aviremia was observed in the ChAd-NS boost, 
DNA boost, and high-dose ChAd-NS groups at 
a frequency of 50%, 33%, and 17%, respectively 
(Supporting Fig. S5C), but was not observed for any 
rat receiving a single dose of 1 × 108 i.u. ChAd-NS 
(Fig. 4B,C).
Fig. 2. Blood CD8+IFNγ+ immune responses to RHV infection in unvaccinated rats. Six male SD rats were infected with 106 vp of RHV 
by intravenous injection into the tail vein. PBMCs were isolated and stimulated with eight pools of overlapping 15-mer peptides spanning 
the entire polypeptide sequence of RHV. Blood samples were taken weekly for 4 weeks postinfection to chart a time course of blood 
CD8+IFNγ+ responses by flow cytometry.
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IMMUNe ReSpoNSeS IN 
VaCCINateD, CHalleNgeD 
RatS aND aSSoCIatIoN WItH 
pRoteCtIoN
To determine whether differences in cellular 
responses might be responsible for different chal-
lenge outcomes, immune responses prechallenge 
and postchallenge and their association with protec-
tion were compared between groups (Figs. 5 and 6; 
Supporting Figs. S6 and S7). Two marked differ-
ences were observed between rats vaccinated with the 
standard dose of 1 × 108 i.u. and those boosted with 
ChAd-NS or DNA-NS or administered a higher 
single dose of ChAd-NS. The latter three groups 
showed higher recall of CD4 (Supporting Fig. S6B) 
and CD8 (Fig. 5B) responses 28 days postinfection, 
particularly against NS4. There were no clear dif-
ferences in cellular immune responses between vac-
cine groups prior to challenge (Supporting Fig. S6A; 
Fig. 5A) or at EOT (Supporting Fig. S6C,D; 
Fig. 5C-E). The population of liver-infiltrating CD8+ 
lymphocytes remained at high levels until EOT in all 
vaccinated groups (Fig. 5E).
Cellular responses varied markedly with outcome 
(Fig. 6D-F; Supporting Figs. S8 and S9). To test for 
statistically significant associations between cellular 
immune responses and infection resolution, vacci-
nated rats were divided into two groups: “controllers” 
with undetectable viremia and “noncontrollers” with 
high viremia, at EOT (Supporting Fig. S5B). Two 
rats showing early control but later breakthrough 
Fig. 3. CD8+IFNγ+ cellular immune responses following vaccination of rats with an adenoviral vectored vaccine encoding the nonstructural 
proteins of RHV (ChAd-NS). Four male SD rats were vaccinated intramuscularly with 108 i.u. per dose of an adenoviral (ChAdOx1) 
vectored vaccine encoding the nonstructural proteins of RHV shown in (A). Truncated shark invariant chain was used as a genetic 
adjuvant. PBMCs were isolated from blood drawn weekly from vaccinated rats and stimulated with four pools of overlapping peptides 
representing the nonstructural regions of RHV. (B) The time course of CD8+IFNγ+ responses for 4 weeks postvaccination, as measured 
using flow cytometry; plotted are pooled responses against all four peptide pools for each rat. Mock-vaccinated rats are shown with 
hatched lines. (C-E) Immune responses by flow cytometry 4 weeks postvaccination against the four individual peptide pools as shown for 
PBMCs, splenocytes, and liver-infiltrating lymphocytes, respectively, with mock-vaccinated rats shown as unfilled symbols. Abbreviations: 
CMV, cytomegalovirus; SIi, shark invariant chain.
A
B C
D E
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infection were classified as controllers. CD4+IFNγ+ 
(Supporting Fig. S7) and CD8+IFNγ+ (Fig. 6) 
responses were higher in controllers than noncon-
trollers. This association was statistically signifi-
cant only with CD8+IFNγ+ responses against NS4 
postchallenge (Fig. 6B,C; Supporting Fig. S7E,F). 
Splenocyte, but not liver-infiltrating lymphocyte, 
CD8+IFNγ+ responses correlated with PBMC 
CD8+IFNγ+ responses (Supporting Fig. S7D), 
suggesting that responses in the liver are not repre-
sentative of those measured in the blood, providing 
one possible explanation for the lack of correla-
tion between prechallenge PBMCs and challenge 
outcome.
t-Cell eSCape MUtatIoNS
Two rats vaccinated with ChAd-NS showed 
initial control of RHV infection but subsequent 
breakthrough infection (Fig. 5B,C, thick lines). To 
determine whether this was caused by T-cell escape 
mutants, the RHV genome sequence from one 
breakthrough rat was isolated (Fig. 5C) and com-
pared to RHV sequences from two nonvaccinated 
rats. Seventeen–amino acid substitutions were dis-
covered across 14 putative nonamer T-cell epitopes 
(SYFPEITHI software prediction) (Supporting 
Table S2). The vaccinated breakthrough rat had all 
but one of these mutations, with the RHV-infected 
unvaccinated rats showing mutations in five to seven 
sites. Two of the mutated nonamers derived from 
15-mer sequences identified as immunodominant in 
vaccinated rats (Supporting Table S2 and Fig. S4B,C). 
These nonamers as wild-type were immunogenic 
by ELISpot, whereas responses against the mutant 
forms were lower in the breakthrough rat (Fig. 5F). 
Interestingly, the epitope MVGHAFLTY from NS4B, 
associated with resolution of infection (Fig. 6), con-
tained three mutated sites in the RHV isolated from 
the breakthrough rat. Two of these mutated sites, the 
FIg. 4. Protective efficacy of ChAd-NS vaccination strategies against challenge with RHV. Male SD rats (n = 6/group) were vaccinated 
and challenged as described in Table 1. Vaccinations were administered by intramuscular injection into the right hind leg. Four weeks 
following vaccination RHV was administered by intravenous injection into a tail vein. (A) Mock-vaccinated rats, challenged with either 
105 or 106 vp RHV. (B-F) Rats vaccinated and challenged as indicated. Viremia at each time point obtained by quantitative PCR against 
a standard curve of RHV genomes of known concentration.
A B C
D E F
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underlined valine and alanine residues, were predicted 
to serve as anchor residues for contiguous nonamer 
epitopes within the 15-mer peptide.
IMMUNogeNICIty aND 
eFFICaCy oF aDeNoVIRUS 
eNCoDINg RHV StRUCtURal 
aNtIgeNS (Chad-S) aloNe aND 
IN CoMBINatIoN WItH Chad-NS
To investigate the role of RHV antigen target 
in protection, a ChAdOx1-based vaccine encoding 
structural antigens, ChAd-S, was used to vaccinate 
six SD rats at 1 × 108 i.u. per dose. A second set of 
rats (n = 6) were vaccinated with a combination of 
ChAd-S+ChAd-NS, with each distinct vaccine used 
at 1 × 108 i.u. within the mixture. Four weeks post-
vaccination rats were challenged with 1  ×  105 vp. 
ChAd-S-vaccinated rats showed no evidence of 
viral control postinfection (Fig. 7A). However, the 
combination of ChAd-S+ChAd-NS showed supe-
rior viral control at all time points compared against 
ChAd-S alone and ChAd-NS alone (Fig. 7B): 
83% of ChAd-S+ChAd-NS-vaccinated rats cleared 
infection by EOT, compared to 0% for ChAd-S-
vaccinated and 50% for ChAd-NS-vaccinated rats 
(Fig. 7C).
Analysis of cellular immune responses revealed no 
difference between single or combination vaccination 
groups in CD4+IFNγ+ or CD8+IFNγ+ responses prior 
to infection, for any structural or nonstructural antigen 
(Supporting Figs. S10A,D and S11A,D). CD8+IFNγ+ 
FIg. 5. Effects on CD8+IFNγ+ cellular immunogenicity of different vaccination regimes and putative escape mutation. Male SD rats 
(n = 6/group) were vaccinated and challenged 4 weeks after final vaccination as described in Table 1. CD8+IFNγ+ responses from PBMCs 
are shown (A) 2 days prior to infection, (B) 4 weeks postinfection, and (C) at EOT. CD8+IFNγ+ responses at EOT are shown for 
(D) splenocytes and (E) liver-infiltrating lymphocytes. (F) A rat vaccinated by intramuscular injection of 108 i.u. ChAd-NS and challenged 
4 weeks later by intravenous injection of 106 vp of RHV showed initial control of virus but subsequent breakthrough infection. RHV 
RNA was isolated from serum taken following breakthrough and sequence data obtained by next generation sequencing. Shown are the 
ELISpot responses from splenocytes stimulated with either wild-type (black bars) or mutant (gray bars) forms of putative T-cell epitopes 
(epitopes listed as wild-type sequences). Abbreviation: SFU, spot-forming unit.
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responses to structural antigens prior to challenge 
were focused on E1 and E2 (Supporting Fig. S11D) 
but broadened to include core and NS2 postchal-
lenge (Fig. 7D). CD4+IFNγ+ responses to NS3 and 
CD8+IFNγ+ responses to NS3 and NS4 were signifi-
cantly augmented compared to ChAd-NS-vaccinated 
rats 28 days postinfection (Fig. 7E,F). The improved 
efficacy seen with the ChAd-S+ChAd-NS combi-
nation compared to single-vaccine groups may result 
from an augmented response to NS4, a broadening of 
the immune response to include structural antigens, 
or both.
Discussion
RHV infection of SD rats has enabled a compre-
hensive evaluation of the efficacy of several differ-
ent vaccine strategies within a small animal HCV 
model. Using a homologous prime-boost approach 
with a simian adenovirus vaccine encoding non-
structural antigens, 100% resolution of infection 
was obtained. This study also established that a cel-
lular immune response can prevent any detectable 
infection by a hepacivirus postchallenge in a vacci-
nated animal. In summary, the current study estab-
lishes the utility of the RHV SD challenge model 
for rapid and inexpensive assessment of vaccine 
regimes congruous with current ethical scientific 
guidelines. The model will be crucial in developing 
the next-generation HCV vaccine, work urgently 
required given the failure of the first clinical trial of 
HCV vaccine efficacy (NCT01436357).(10) In that 
trial, viral-vectored delivery of nonstructural HCV 
antigens showed no efficacy. Here, we have shown 
that the addition of structural to nonstructural anti-
gens markedly enhances efficacy. Other strategies 
can be explored using the RHV rat model, but most 
crucially it will be of use in gaining an understand-
ing of the mechanisms of vaccine-induced protec-
tive immunity, enabling rational selection of the 
next-generation HCV vaccine.
Similarly to inbred Lewis rats,(7) RHV infection of 
unvaccinated SD rats elicited little detectable T-cell 
FIg. 6. Association of CD8+IFNγ+ cellular immune responses with protection. Male SD rats (n = 6/group) were vaccinated and challenged 
4 weeks after final vaccination as described in Table 1. Rats were divided into two groups, "controllers" and "noncontrollers," on the basis 
of possessing detectable viremia or otherwise at EOT. Associations of CD8+IFNγ+ responses from PBMCs are shown (A) 2 days prior to 
infection, (B) 4 weeks postinfection, and (C) at EOT. Numbers on graphs represent significant P values between indicated groups using 
analysis of variance with Bonferroni’s multiple comparison test. Representative time courses of cellular responses and viremia in three 
vaccinated rats which (D) did not control infection, (E) resolved an infection, or (F) showed no detectable infection.
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response. In humans a lack of CD4+ response during 
acute infection is associated with development of HCV 
chronicity.(29,30) Consistent with this, all naive SD rats 
infected with RHV in this study maintained high 
viremia for approximately 150 days, with no sponta-
neous resolution. The absence of reactive CD8+ T cells 
against RHV contrasts with detectable levels in nearly 
all humans acutely infected with HCV(31); their being 
largely absent in RHV-infected rats suggests that RHV 
may possess some additional mechanism of control of 
host cellular response or that the high levels of early 
viral replication exacerbate the tolerance mechanisms 
associated with liver presentation, seen in high-dose 
adenovirus models.(32) Given the lack of immunoge-
nicity of RHV challenge in naive rats and the lack of 
spontaneous control in this model compared to human 
infection with HCV, the protection data shown here 
are encouraging that this vaccine approach could pro-
vide robust protection in a clinical setting.
Vaccination with ChAd-NS induced a strong 
CD8+IFNγ+ response, focused on NS4, but no detect-
able CD4+IFNγ+ response. In other studies, adeno-
viruses delivering HCV NS proteins show a similar 
skew toward CD8+ T lymphocytes in humans,(3,33,34) 
macaques,(35,36) and Lewis rats.(7) Similar to our find-
ings, boosting with a second adenovirus did little to 
increase CD8+ or CD4+ T-lymphocyte responses in 
humans, but an MVA boost did markedly increase 
both(34); it will be of interest to determine whether 
an adenovirus/MVA prime-boost regime demon-
strates the same profile of immunogenicity in rats and 
whether this results in enhanced protection against 
RHV challenge.
The efficacy (42%) of ChAd-NS against RHV in 
SD rats was of the same magnitude seen using a 5-fold 
higher dose of adenovirus serotype 5 (HuAd5) to 
deliver NS antigens in Lewis rats (66%).(7) The CD4+ 
response has been established as important for control 
FIg. 7. Protective efficacy of ChAd-S alone and in combination with ChAd-NS. Male SD rats (n  =  6/group) were vaccinated by 
intramuscular injection with either ChAd-S, ChAd-NS, or premixed ChAd-S and ChAd-NS at a dose of 108 i.u. per distinct vaccine. 
Four weeks following vaccination, rats were challenged by intravenous injection into the tail vein of 105 vp RHV. Blood viremia was traced 
weekly postinfection by real-time quantitative PCR against a standard curve of RHV RNA for (A) ChAd-S-vaccinated and (B) ChAd-S + 
ChAd-NS–vaccinated rats. (C) Viremia at EOT. Blood cellular immune responses were compared by flow cytometry for single-vaccine 
versus combination groups for (D) CD8+IFNγ+ responses to structural antigens and (E) CD4+IFNγ+ and (F) CD8+IFNγ+ responses to 
nonstructural antigens at 28 days postchallenge.
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of HCV in chimpanzees,(37) humans,(29,30) and Lewis 
rats.(7) It will be of interest to see if CD4+ T cells play 
the same role in the protection against RHV in SD 
rats; no evidence of an association of CD4+IFNγ+ 
responses with protection was found here. Another 
potential difference between the two models is the 
specific role of the adenovirus backbone in driving 
protective immunity. HuAd5 has limited capacity 
for translation due to widespread prior immunity,(38) 
while ChAdOx1 is associated with higher levels of 
innate activation with strong translational potential 
due to lack of preexisting antibody.(39,40) The exact 
role of innate activation in the adjuvanticity of ade-
noviral vector biology is still not fully understood but 
can impact on immunogenicity and therefore protec-
tive capacity.(41,42)
Boosting with ChAd-NS or DNA-NS or using a 
7-fold higher single dose enhanced resolution com-
pared to ChAd-NS at the standard priming dose. 
One third of these rats (6/18) showed no detectable 
RHV viremia at any time point, an outcome not 
seen with the standard dose of ChAd-NS in SD or 
Lewis rats.(7) This result demonstrates that a subop-
timal vaccination regime against a hepacivirus can be 
transformed into a highly protective regime through 
boosting or a higher single dose, suggesting that in 
the case of clinical trials of HCV vaccines resulting in 
low but statistically significant efficacy, large improve-
ments could be achievable with minor adjustments in 
the vaccination regimen, warranting such further clin-
ical testing.
The improved efficacy of the boost or higher 
prime-dose regimes was associated with a stronger 
CD8+IFNγ+ recall response in blood, spleen, and liver 
but not with blood cellular responses prior to challenge. 
The inability of prechallenge blood cellular responses 
to predict postchallenge outcome suggests that some 
aspect of immunity not measured here may be a bet-
ter preinfection vaccine correlate of protection, such 
as memory,(18,37,43) liver-residence(43) polyfunctional-
ity, or granzyme expression. It is worth noting that 
we observed no correlation between liver-infiltrating 
lymphocytes and PBMC responses at EOT, and in a 
study in vaccinated Lewis rats RHV-specific CD4+ T 
cells were detectable only in the liver postchallenge, 
not in the spleen.(7) In one chimpanzee vaccine study, 
vaccine-induced CD8+ alone did not associate with 
protection, but CD8+ markers of activation did.(19) In 
another chimpanzee vaccine study, proinflammatory 
cytokines in the liver did not, whereas markers of 
tolerance did, associate with challenge outcome.(44) 
These studies demonstrate the potential complexities 
in defining a reliable prechallenge correlate of protec-
tion.(45) One of the most practical applications of the 
rat RHV model will be to determine a reliable vaccine 
correlate of protection that can apply to clinical tri-
als of HCV vaccines, which, if validated in humans, 
would enhance progress in HCV vaccine develop-
ment by obviating the need for challenge studies for 
each vaccine. Further mechanistic work will also be 
required to explain cases of aviremia, with available 
data not suggesting a clear role for either cellular or 
humoral responses.
A well-defined feature of HCV infection is CD8+ 
T-cell escape mutants contributing to persistence,(37,46) 
also observed in Lewis rats.(7) Mutations were found 
concurrently in both the immunodominant CD8+ 
T-cell epitopes defined in the present study; given that 
SD rats are outbred and the major histocompatibility 
complexes were not haplotyped, this is suggestive of 
escape mutation but not conclusive. It is not known 
whether T-cell escape mutations can be prevented 
with a sufficiently strong immune response to vacci-
nation; interestingly, in this study, the two rats wherein 
escape mutants arose were administered the subop-
timal single-prime dose of ChAd-NS (2/12 rats), 
whereas breakthrough infections were not observed 
in any of the rats vaccinated with the more protec-
tive boost or high-priming dose regimes. Two further 
questions could be answered, exploiting viral escape 
in the rat RHV model. Firstly, an escape mutant can 
allow heterologous challenge to be approximated in 
the rat RHV model. Secondly, a vaccine missing the 
immunodominant epitopes could be constructed to 
test the hypothesis that its absence will increase the 
cellular immune response to subdominant epitopes(47) 
and whether this strategy enhances efficacy.
The strategy to broaden the immune response to 
both structural and nonstructural antigens by com-
bining ChAd-NS with ChAd-S clearly demon-
strated enhanced efficacy compared to either vaccine 
alone. The exact mechanism for enhanced protec-
tion is unclear as alone ChAd-S confers no efficacy. 
Nevertheless, this combination shows the highest-level 
efficacy of any single-shot vaccination regimen tested 
in rats. It is remarkable that the addition of a vaccine 
which shows no protection alone has such a profound 
impact in this challenge model. Given the clear role for 
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immune escape seen in vaccine failure, one explanation 
could be driving a critical threshold of breadth, seen 
as critical in many T-cell vaccine strategies.(48) Because 
these antigens were delivered using separate adenovi-
ruses, this may also have served to allow for maximiza-
tion of breadth, as recently observed using adenovirus 
vectors in murine studies.(49,50) Antibodies raised by 
the structural antigens may also play a role in protec-
tion; passive antibody transfer to naive and ChAd-NS-
vaccinated rats will determine this more fully.
Further work using this model can now proceed to 
investigate other vaccination platforms, adjuvants, and 
antigen combinations, all of which will inform and 
accelerate clinical vaccine development for HCV. The 
extremely high levels of protection obtained both by 
prime-boost regimes and by a single-shot vaccination 
strategy combining structural and nonstructural anti-
gens warrant further mechanistic investigation. Such 
investigation would be of great utility in designing 
optimal vaccines for humans; the ease of working with 
rats will allow a reliable vaccine correlate of protec-
tion to be established for high-level protection against 
HCV-like hepaciviruses.
Acknowledgment: We thank Angela Curran and Richard 
Maxwell for their care and attention to the rats used in 
this study. We thank Adrian Hill and Sarah Gilbert for 
access to ChAdOX1.
ReFeReNCeS
 1) World Health Organization. Global hepatitis report, 2017. Geneva, 
Switzerland: World Health Organization; 2017.
 2) Gravitz L. Introduction: a smouldering public-health crisis. Nature 
2011;474:2.
 3) Bailey JR, Barnes E, Cox AL. Approaches, progress, and chal-
lenges to hepatitis C vaccine development. Gastroenterology 2019; 
156:418-430.
 4) Billerbeck E, de Jong Y, Dorner M, de la Fuente C, Ploss A. 
Animal models for hepatitis C. Curr Top Microbiol Immunol 
2013;369:49-86.
 5) Firth C, Bhat M, Firth MA, Williams SH, Frye MJ, Simmonds 
P, et al. Detection of zoonotic pathogens and characterization of 
novel viruses carried by commensal Rattus norvegicus in New York 
City. MBio 2014;5:1933.
 6) Trivedi S, Murthy S, Sharma H, Hartlage AS, Kumar A, Gadi SV, 
et al. Viral persistence, liver disease, and host response in a hepatitis 
C–like virus rat model. Hepatology 2018;68:435-448.
 7) Hartlage AS, Murthy S, Kumar A, Trivedi S, Dravid P, Sharma H, 
et al. Vaccination to prevent T cell subversion can protect against 
persistent hepacivirus infection. Nat Commun 2019;10:1113.
 8) Cox AL, Thomas DL. Hepatitis C virus vaccines among people 
who inject drugs. Clin Infect Dis 2013;57(Suppl. 2):46.
 9) Cox AL, Page K, Bruneau J, Shoukry NH, Lauer GM, Kim AY, 
et al. Rare birds in North America: acute hepatitis C cohorts. 
Gastroenterology 2009;136:26-31.
 10) Trial evaluating experimental hepatitis C vaccine concludes [press 
release]. Atlanta: National Institutes of Health, National Institute 
of Allergy and Infectious Diseases; May 29, 2019. Available at: 
https ://www.niaid.nih.gov/news-event s/trial-evalu ating-exper 
iment al-hepat itis-c-vacci ne-concl udes.
 11) Chen J, Zhao y, Zhang C, Chen H, Feng J, Chi X, et al. 
Persistent hepatitis C virus infections and hepatopathological 
manifestations in immune-competent humanized mice. Cell Res 
2014;24:1050-1066.
 12) Ilan E, Arazi J, Nussbaum O, Zauberman A, Eren R, Lubin I, et al. 
The hepatitis C virus (HCV)–trimera mouse: a model for evalua-
tion of agents against HCV. J Infect Dis 2002;185:153-161.
 13) Galun E, Burakova T, Ketzinel M, Lubin I, Shezen E, Kahana Y, 
et al. Hepatitis C virus viremia in SCID → BNX mouse chimera.  
J Infect Dis 1995;172:25-30.
 14) Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G,  
et al. Vaccination of chimpanzees against infection by the hepatitis 
C virus. Proc Natl Acad Sci USA 1994;91:1294-1298.
 15) Houghton M. Prospects for prophylactic and therapeutic vaccines 
against the hepatitis C viruses. Immunol Rev 2011;239:99-108.
 16) Rollier C, Depla E, Drexhage JAR, Verschoor EJ, Verstrepen BE, 
Fatmi A, et al. Control of heterologous hepatitis C virus infection 
in chimpanzees is associated with the quality of vaccine-induced 
peripheral T-helper immune response. J Virol 2004;78:187-196.
 17) Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole 
BB, et al. A T-cell HCV vaccine eliciting effective immunity 
against heterologous virus challenge in chimpanzees. Nat Med 
2006;12:190-197.
 18) park S, Shin e, Capone S, Caggiari L, De Re V, Nicosia A,  
et al. Successful vaccination induces multifunctional memory 
T-cell precursors associated with early control of hepatitis C virus. 
Gastroenterology 2012;143:1060.
 19) Zubkova I, Duan H, Wells F, Mostowski H, Chang E, Pirollo K,  
et al. Hepatitis C virus clearance correlates with HLA-DR expres-
sion on proliferating CD8+ T cells in immune-primed chimpan-
zees. Hepatology 2014;59:803-813.
 20) Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, 
et al. Spontaneous control of primary hepatitis C virus infection 
and immunity against persistent reinfection. Gastroenterology 
2010;138:315-324.
 21) Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, 
Thomas DL, et al. Clearance of hepatitis C infection is associated 
with the early appearance of broad neutralizing antibody responses. 
Hepatology 2014;59:2140-2151.
 22) pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset 
F, et al. Rapid induction of virus-neutralizing antibodies and viral 
clearance in a single-source outbreak of hepatitis C. Proc Natl 
Acad Sci USA 2007;104:6025-6030.
 23) Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang 
X-H, et al. Cross-genotype immunity to hepatitis C virus. J Virol 
2004;78:1575-1581.
 24) Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, 
Balfe P, et al. Neutralizing antibody response during acute and 
chronic hepatitis C virus infection. Proc Natl Acad Sci USA 
2004;101:10149–10154.
 25) Simmonds P. Genetic diversity and evolution of hepatitis C virus—
15 years on. J Gen Virol 2004;85:3173-3188.
 26) von Delft a, Donnison ta, Lourenço J, Hutchings C, Mullarkey 
CE, Brown A, et al. The generation of a simian adenoviral vectored 
HCV vaccine encoding genetically conserved gene segments to 
target multiple HCV genotypes. Vaccine 2018;36:313-321.
 27) Altevogt BM, Pankevich DE, Pope AM, Kahn JP. Guiding limited 
use of chimpanzees in research. Science 2012;335:41-42.
 28) Halbroth BR, Sebastian S, Poyntz HC, Bregu M, Cottingham 
MG, Hill AVS, et al. Development of a molecular 
Hepatology, Vol. 71, No. 3, 2020 ATCHESON ET AL.
807
adjuvant to enhance antigen-specific CD8+ T cell responses. Sci 
Rep 2018;8:15020-15014.
 29) Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari 
FV. Determinants of viral clearance and persistence during 
acute hepatitis C virus infection. J Exp Med 2001;194:1395- 
1406.
 30) Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut 
WW, Zachoval R, et al. Recurrence of hepatitis C virus after 
loss of virus-specific CD4+ T-cell response in acute hepatitis C. 
Gastroenterology 1999;117:933-941.
 31) Kaplan DE, Sugimoto K, Newton K, Valiga ME, Ikeda F, Aytaman 
A, et al. Discordant role of CD4 T-cell response relative to neu-
tralizing antibody and CD8 T-cell responses in acute hepatitis C. 
Gastroenterology 2007;132:654-666.
 32) Krebs P, Scandella E, Odermatt B, Ludewig B. Rapid functional 
exhaustion and deletion of CTL following immunization with re-
combinant adenovirus. J Immunol 2005;174:4559-4566.
 33) Barnes e, Folgori a, Capone S, Swadling L, Aston S, Kurioka 
A, et al. Novel adenovirus-based vaccines induce broad and sus-
tained T cell responses to HCV in man. Sci Transl Med 2012;4: 
115ra1.
 34) Swadling l, Capone S, antrobus RD, Brown A, Richardson 
R, Newell EW, et al. A human vaccine strategy based on chim-
panzee adenoviral and MVA vectors that primes, boosts, and 
sustains functional HCV-specific T cell memory. Sci Transl Med 
2014;6:261ra153.
 35) Fattori E, Zampaglione I, Arcuri M, Meola A, Ercole BB, Cirillo 
A, et al. Efficient immunization of rhesus macaques with an 
HCV candidate vaccine by heterologous priming-boosting with 
novel adenoviral vectors based on different serotypes. Gene Ther 
2006;13:1088-1096.
 36) Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, Ruggeri 
L, et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus 
vector that overcomes preexisting anti-Ad5 immunity and induces 
potent and broad cellular immune responses in rhesus macaques.  
J Virol 2006;80:1688-1699.
 37) Grakoui A, Shoukry NH, Woollard DJ, Han J, Hanson HL, 
Ghrayeb J, et al. HCV persistence and immune evasion in the ab-
sence of memory T cell help. Science 2003;302:659-662.
 38) Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton 
MK, Borgerding J, et al. Merck Ad5/HIV induces broad innate 
immune activation that predicts CD8+ T-cell responses but is at-
tenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 
2012;109:E3503-E3512.
 39) Dicks MDJ, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert 
SC, et al. A novel chimpanzee adenovirus vector with low human 
seroprevalence: improved systems for vector derivation and com-
parative immunogenicity. PLoS One 2012;7:e40385.
 40) Colloca S, Barnes e, Folgori A, Ammendola V, Capone S, Cirillo 
A, et al. Vaccine vectors derived from a large collection of sim-
ian adenoviruses induce potent cellular immunity across multiple  
species. Sci Transl Med 2012;4:115ra2.
 41) Kazmin D, Nakaya HI, Lee EK, Johnson MJ, van der Most R, 
van den Berg RA, et al. Systems analysis of protective immune  
responses to RTS, S malaria vaccination in humans. Proc Natl 
Acad Sci USA 2017;114:2425-2430.
 42) Teigler JE, Iampietro MJ, Barouch DH. Vaccination with adenovi-
rus serotypes 35, 26, and 48 elicits higher levels of innate cytokine 
responses than adenovirus serotype 5 in rhesus monkeys. J Virol 
2012;86:9590-9598.
 43) Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, 
Reimann KA, et al. Memory CD8+ T cells are required for pro-
tection from persistent hepatitis C virus infection. J Exp Med 
2003;197:1645-1655.
 44) Rollier CS, Paranhos-Baccala G, Verschoor EJ, Verstrepen BE, 
Drexhage JAR, Fagrouch Z, et al. Vaccine-induced early con-
trol of hepatitis C virus infection in chimpanzees fails to im-
pact on hepatic PD-1 and chronicity. Hepatology 2007;45: 
602-613.
 45) Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C 
virus vaccine efficacy in chimpanzees indicates an importance for 
structural proteins. Gastroenterology 2010;139:965-974.
 46) Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, 
et al. CD8 epitope escape and reversion in acute HCV infection.  
J Exp Med 2004;200:1593-1604.
 47) Tscharke DC, Croft NP, Doherty PC, La Gruta NL. Sizing up the 
key determinants of the CD8+ T cell response. Nat Rev Immunol 
2015;15:705-716.
 48) Panagioti E, Klenerman P, Lee LN, van der Burg Sjoerd H, Arens 
R. Features of effective T cell-inducing vaccines against chronic 
viral infections. Front Immunol 2018;9:276.
 49) Lee LN, Bolinger B, Banki Z, de Lara C, Highton AJ, Colston 
JM, et al. Adenoviral vaccine induction of CD8+ T cell memory 
inflation: impact of co-infection and infection order. PLoS Pathog 
2017;13:e1006782.
 50) Colston JM, Bolinger B, Cottingham MG, Gilbert S, Klenerman P. 
Modification of antigen impacts on memory quality after adenovi-
rus vaccination. J Immunol 2016;196:3354-3363.
Author names in bold designate shared co-first authorship.
Supporting Information
Additional Supporting Information may be found at 
onlinelibrary.wiley.com/doi/10.1002/hep.30894/suppinfo. 
